9th Annual Biomarkers Congress
Eighth International Symposium on Ovarian Cancer and Gynecologic Malignancies
The Westin New York at Times Square - Majestic Ballroom
270 W. 43rd St. at 8th Ave.
, New York 10036
http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/653
   Deadlines
   ---------

     *  Abstract Deadline:
       25th February 2011


   Speakers
   --------

   Robert A. Burger,
   Robert L. Coleman,
   Allan Covens,
   Eric L. Eisenhauer,
   Thomas J. Herzog,
   Robert S. Mannel,
   Maurie Markman,
   David Scott Miller,
   Gillian Thomas

   The Eighth International Symposium on Ovarian Cancer and Other
   Gynecologic Malignancies will provide oncologists and other health
   care professionals with the latest information on the treatment of
   these diseases. Debates and lectures will discuss current standards of
   care and treatment guidelines, promising novel agents, and
   controversies in the management of patients with these malignancies.

   Topics include:

     *  The role of cytoreduction in patients with ovarian cancer

     *  Intraperitoneal chemotherapy in ovarian cancer

     *  Optimal chemotherapy choices for advanced ovarian cancer

     *  The use of CA-125 and in vitro assays in treatment decision
       making

     *  HPV vaccination

     *  Controversies in the treatment of cervical and uterine cancers

     *  Staging and treatment of endometrial cancer

     *  New agents under investigation (antiangiogenic therapy, PARP
       inhibitors, folate receptor antagonists, PI3K pathway inhibitors)


   270 W. 43rd St. at 8th Ave., New York, NY , 10036, United States

   Loading (May not complete on browsers without Javascript support)...

   Try again

Schedule of Presentations:

Friday, March 25, 2011
07:00:00 Registration and Continental Breakfast
07:50:00 Welcome, Introductions, and Presession Survey J. Tate Thigpen
07:55:00 Debate 1 | HPV vaccination should be administered to all children prior to the onset of puberty. J. Tate Thigpen
08:00:00 PRO Thomas J. Herzog
08:15:00 CON Kevin Ault
08:30:00 Question and Answer Session
08:35:00 Debate 2 | Proper staging and management of endometrial cancer must include a lymph node dissection.
08:40:00 PRO
08:55:00 CON Allan Covens
09:10:00 Question and Answer Session
09:15:00 Options for the Treatment of Patients With Recurrent Carcinoma of the Uterine Cervix Michael J. Birrer
09:20:00 Role of Surgery Eric L. Eisenhauer
09:35:00 Role of Radiation Therapy Marcus Randall
09:50:00 Role of Systemic Therapy J. Tate Thigpen
10:05:00 Panel Discussion
10:20:00 Break
10:35:00 New Agents and Translational Research Michael J. Birrer
10:40:00 New Antiangiogenesis Agents
11:00:00 Polo Kinase Inhibitors
11:20:00 Immunotherapy George Coukos
11:40:00 Lunch on Own
13:05:00 Debate 3 | The postoperative adjuvant therapy of choice in patients with complete gross resection of carcinosarcoma of the uterus is Marcus Randall
13:10:00 Observation
13:25:00 Chemotherapy David Scott Miller
13:40:00 Combined Modality Therapy Gillian Thomas
13:55:00 Question and Answer Session
14:10:00 Case Presentations and Discussions
15:35:00 Debate 4 | Patients with stage III-IV ovarian cancer who achieve a clinical complete response to initial systemic treatment should receive maintenance therapy.
15:40:00 PRO
15:55:00 CON
16:10:00 Question and Answer Session
16:25:00 Postsession Survey J. Tate Thigpen
16:30:00 Adjourn
Saturday, March 26, 2011
07:30:00 Registration and Continental Breakfast
07:50:00 Welcome, Introductions, and Presession Survey J. Tate Thigpen
07:55:00 Debate 5 | Management of stage III ovarian cancer should start with an aggressive attempt at surgical cytoreduction unless specifically contraindicated by the patient’s medical condition.
08:00:00 PRO
08:15:00 CON
08:30:00 Question and Answer Session
08:35:00 Debate 6 | Chemotherapy should replace radiation therapy as the postoperative treatment of choice in endometrial cancer.
08:40:00 PRO
08:55:00 CON
09:10:00 Question and Answer Session
09:15:00 Debate 7 | Patients with small-volume residual stage III ovarian cancer should receive intraperitoneal systemic therapy after surgery.
09:20:00 PRO
09:35:00 CON
09:50:00 Question and Answer Session
10:00:00 Break
10:15:00 New Agents and Translational Research Michael J. Birrer
10:20:00 Topoisomerase Inhibitors Thomas J. Herzog
10:40:00 Folate Receptor Antagonists
11:00:00 PARP Inhibitors Michael J. Birrer
11:20:00 Lunch on Own
12:45:00 Debate 8 | For patients with advanced ovarian cancer, initial surgery should be followed by
12:50:00 Every-3-Week Taxane Platinum Antiangiogenic Therapy Robert A. Burger
13:10:00 Weekly Taxane Every-3-Week Platinum
13:30:00 Every-3-Week Taxane Platinum Robert S. Mannel
13:50:00 Discussion | Question-and-Answer Session
14:10:00 Case Presentations and Discussion J. Tate Thigpen
15:05:00 Debate 9 | CA-125 should not be routinely used to follow patients with advanced ovarian cancer in clinical complete response after initial systemic therapy. Marcus Randall
15:10:00 PRO Allan Covens
15:25:00 CON J. Tate Thigpen
15:40:00 Question and Answer Session
15:45:00 Debate 10 | Selection of systemic therapy for patients with platinum-resistant recurrent ovarian cancer is best accomplished by using results of in vitro assays of sensitivity and/or resistance.
15:50:00 PRO
16:05:00 CON Michael J. Birrer
16:20:00 Question and Answer Session
16:30:00 Postsession Survey J. Tate Thigpen
16:40:00 Adjourn
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.